Publications

The New England journal of medicine

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

09-11-2023

The New England journal of medicine

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

09-11-2023

Journal of the National Cancer Institute

Financial outcomes of adolescent and young adult cancer survivors: a longitudinal population-based registry study.

08-11-2023

Journal of the National Cancer Institute

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.

08-11-2023

Expert review of molecular diagnostics

Cross-sectional risk models using quantitative fecal hemoglobin in colorectal cancer screening: a systematic review.

06-11-2023

The Journal of antimicrobial chemotherapy

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.

06-11-2023

The Journal of experimental medicine

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

06-11-2023

Journal for immunotherapy of cancer

Quantifying the impact of immunotherapy on RNA dynamics in cancer.

01-11-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.

01-11-2023

Clinical and translational radiation oncology

Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study).

01-11-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reply to G. Wang et al.

01-11-2023

European journal of cancer (Oxford, England : 1990)

Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).

01-11-2023

Nature structural & molecular biology

Molecular mechanisms of inorganic-phosphate release from the core and barbed end of actin filaments.

01-11-2023

Cancer discovery

Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer.

01-11-2023

Cancer immunology, immunotherapy : CII

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

01-11-2023

Cancer medicine

Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators.

01-11-2023

Cancer discovery

Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

01-11-2023

Nature genetics

Author Correction: Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

01-11-2023

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need.

01-11-2023

European urology

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

01-11-2023

European journal of cancer (Oxford, England : 1990)

Diagnostic accuracy of CT for local staging of colon cancer: A nationwide study in the Netherlands.

01-11-2023

Nature medicine

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.

01-11-2023

The British journal of radiology

Sense and non-sense of imaging in the era of organ preservation for rectal cancer.

01-11-2023

Journal of cancer research and clinical oncology

Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma.

01-11-2023

Paediatric drugs

Azacitidine (Vidaza^®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

01-11-2023

The Lancet. Oncology

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.

01-11-2023

Life science alliance

Grp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis.

01-11-2023

Urologic oncology

Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management.

01-11-2023

The Journal of biological chemistry

STPP-UP: An alternative method for drug target identification using protein thermal stability.

01-11-2023

Biomedical chromatography : BMC

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

01-11-2023

Cell reports

Perturbations in 3D genome organization can promote acquired drug resistance.

31-10-2023

JNCI cancer spectrum

The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.

31-10-2023

BMJ (Clinical research ed.)

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

30-10-2023

Journal of pharmaceutical and biomedical analysis

Validated LC-MS/MS method for simultaneous quantification of KRAS^G12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

25-10-2023

International journal of molecular sciences

Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy.

21-10-2023

Cancers

The Prediction of Biological Features Using Magnetic Resonance Imaging in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

20-10-2023

Science advances

BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis.

20-10-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response.

20-10-2023

Molecular cell

Freedom to err: The expanding cellular functions of translesion DNA polymerases.

19-10-2023

Cell reports. Medicine

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2⁺ breast cancer.

17-10-2023

The EMBO journal

Pioneer activity distinguishes activating from non-activating SOX2 binding sites.

16-10-2023

Cancer

Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis.

15-10-2023

Nucleic acids research

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

13-10-2023

Nucleic acids research

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements.

13-10-2023

BMJ open

Patient-led home-based follow-up after surgery for colorectal cancer: the protocol of the prospective, multicentre FUTURE-primary implementation study.

12-10-2023

Methods in molecular biology (Clifton, N.J.)

Measuring Transcription Dynamics of Individual Genes Inside Living Cells.

12-10-2023

Research square

DDA1, a novel factor in transcription-coupled repair, modulates CRL4^CSA dynamics at DNA damage-stalled RNA polymerase II.

12-10-2023

JMIR research protocols

An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial.

11-10-2023

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Journal of mammary gland biology and neoplasia

Fourteenth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast Cancer.

06-10-2023

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

Financial outcomes of adolescent and young adult cancer survivors: a longitudinal population-based registry study.

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.

Cross-sectional risk models using quantitative fecal hemoglobin in colorectal cancer screening: a systematic review.

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

Quantifying the impact of immunotherapy on RNA dynamics in cancer.

Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.

Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study).

Reply to G. Wang et al.

Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).

Molecular mechanisms of inorganic-phosphate release from the core and barbed end of actin filaments.

Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer.

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators.

Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

Author Correction: Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need.

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

Diagnostic accuracy of CT for local staging of colon cancer: A nationwide study in the Netherlands.

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.

Sense and non-sense of imaging in the era of organ preservation for rectal cancer.

Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma.

Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.

Grp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis.

Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management.

STPP-UP: An alternative method for drug target identification using protein thermal stability.

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

Perturbations in 3D genome organization can promote acquired drug resistance.

The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy.

The Prediction of Biological Features Using Magnetic Resonance Imaging in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis.

Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response.

Freedom to err: The expanding cellular functions of translesion DNA polymerases.

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer.

Pioneer activity distinguishes activating from non-activating SOX2 binding sites.

Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis.

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements.

Patient-led home-based follow-up after surgery for colorectal cancer: the protocol of the prospective, multicentre FUTURE-primary implementation study.

Measuring Transcription Dynamics of Individual Genes Inside Living Cells.

DDA1, a novel factor in transcription-coupled repair, modulates CRL4CSA dynamics at DNA damage-stalled RNA polymerase II.

An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial.

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

Fourteenth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast Cancer.

This site uses cookies

Azacitidine (Vidaza^®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

Validated LC-MS/MS method for simultaneous quantification of KRAS^G12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2⁺ breast cancer.

DDA1, a novel factor in transcription-coupled repair, modulates CRL4^CSA dynamics at DNA damage-stalled RNA polymerase II.